12 Nov A New Era in Clinical Trials

By Edward Triebell, Applied Clinical Trials

The COVID-19 pandemic opened the door for some significant and noteworthy changes to the way our industry could accomplish clinical trials with a forced mandate to decentralize access and services for the continuation of studies.

While COVID-19 provided a gateway for the launch of an unprecedented level of decentralized clinical trial (DCT) services, what we have seen since is a reevaluation of how DCTs should be operationalized. A retraction in the use of services allowed under the FDA variance, corporate restructurings, staff reductions at eClinical technology and service companies, and staff reductions at CROs all demonstrate this shift. We have also seen a significant decrease in the number of sites running clinical trials, thereby exacerbating the existing challenges in recruiting patients.

This stress upon the clinical trials industry might be the perfect pivoting point for committing to innovation and the adoption of new solutions for sites and patients. Decentralized clinical trials have found their way into the spotlight, and with that comes the ability to quickly identify operational gaps and further industry opportunities. Read more…